Draig names Doug Williams chair

Precision neuropsychiatry play Draig Therapeutics Ltd., which raised $120 million in a series A round last month, is adding more experience to its board via the appointment of Doug Williams chair. Williams was most recently president of R&D at cell therapy company Sana Biotechnology Inc. and before that was the founding CEO of Codiak Biosciences Inc. He replaces Ruth McKernan, who will remain on the board and in her role of interim CEO. Draig’s lead program, DT-101, is a positive allosteric modulator of AMPA receptors that the companies believes can treat depression without inducing unwanted side effects.

Another neuropsychiatry company, Allschwi, Switzerland-based  Synendos Therapeutics AG, added depth to its leadership team, naming George Garibaldi as CMO. Garibaldi was co-founder and head of R&D at neurology play Noema Pharma AG, and prior to that was VP and global head of neuroscience development at Roche (SIX:ROG; OTCQX:RHHBY). Synendos’ lead program, SYT-510, is a selective endocannabinoid reuptake inhibitor moving toward Phase II testing...